New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma
Diffuse large B-cell lymphoma and Burkitt lymphoma are two distinct lymphoma entities recognized by the current World Health Organization classification of lymphoid neoplasms. Although diagnostic criteria to distinguish these two subtypes have been established, a subset of cases have overlapping cha...
Gespeichert in:
| Veröffentlicht in: | Best practice & research. Clinical haematology 2012-03, Vol.25 (1), p.3-12 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12 |
|---|---|
| container_issue | 1 |
| container_start_page | 3 |
| container_title | Best practice & research. Clinical haematology |
| container_volume | 25 |
| creator | Frick, Mareike, MD Dörken, Bernd, MD Lenz, Georg, MD |
| description | Diffuse large B-cell lymphoma and Burkitt lymphoma are two distinct lymphoma entities recognized by the current World Health Organization classification of lymphoid neoplasms. Although diagnostic criteria to distinguish these two subtypes have been established, a subset of cases have overlapping characteristics and therefore, the distinction can be challenging. Thus, the World Health Organization classification introduced an intermediate subtype referred as “B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma”. This review summarizes our current understanding of the biology of these lymphoma subtypes. |
| doi_str_mv | 10.1016/j.beha.2012.01.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_927988617</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521692612000047</els_id><sourcerecordid>927988617</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-7967a7a414d5ab0ed211e54f91063a8719672df710bfa08b58a35395729aafdf3</originalsourceid><addsrcrecordid>eNp9kU2PFCEQhonRuOvoH_BguHnqlqI_SYyJu_Er2ehBPROaLmaYpZsR6DX976Uz6x48yIXKy1tviqcIeQmsBAbtm2M54EGVnAEvGZSMVY_IJTQVL0Dw-vFWcyhawdsL8izGYzZUgldPyQXnNRM9iEtiv-Jvaudo94cUc5E8TQekg_XO71fqDZ28Q704FWhchrSeMG7qaI1ZItKs75FeFRqdo26dTgc_KarmkV4t4dam9CA-J0-MchFf3N878vPjhx_Xn4ubb5--XL-_KXQNLBWdaDvVqRrqsVEDw5EDYFMbAaytVN9Bfuej6YANRrF-aHpVNZVoOi6UMqOpduT1OfcU_K8FY5KTjdt4aka_RCl4J_q-hS47-dmpg48xoJGnYCcVVglMboTlUW6E5UZYMpAbwB15dR-_DBOODy1_kWbD27MB8yfvLAYZtcVZ42gD6iRHb_-f_-6fdu3sbLVyt7hiPPolzBmfBBlzj_y-7XhbMXCWT91VfwCiGaGw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>927988617</pqid></control><display><type>article</type><title>New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Frick, Mareike, MD ; Dörken, Bernd, MD ; Lenz, Georg, MD</creator><creatorcontrib>Frick, Mareike, MD ; Dörken, Bernd, MD ; Lenz, Georg, MD</creatorcontrib><description>Diffuse large B-cell lymphoma and Burkitt lymphoma are two distinct lymphoma entities recognized by the current World Health Organization classification of lymphoid neoplasms. Although diagnostic criteria to distinguish these two subtypes have been established, a subset of cases have overlapping characteristics and therefore, the distinction can be challenging. Thus, the World Health Organization classification introduced an intermediate subtype referred as “B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma”. This review summarizes our current understanding of the biology of these lymphoma subtypes.</description><identifier>ISSN: 1521-6926</identifier><identifier>EISSN: 1532-1924</identifier><identifier>DOI: 10.1016/j.beha.2012.01.003</identifier><identifier>PMID: 22409819</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject><![CDATA[Antibodies, Monoclonal, Murine-Derived - administration & dosage ; Antibodies, Monoclonal, Murine-Derived - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Burkitt lymphoma ; Burkitt Lymphoma - classification ; Burkitt Lymphoma - drug therapy ; Burkitt Lymphoma - genetics ; Burkitt Lymphoma - mortality ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - therapeutic use ; diffuse large B-cell lymphoma ; Doxorubicin - administration & dosage ; Doxorubicin - therapeutic use ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Hematology, Oncology and Palliative Medicine ; Humans ; Lymphoma, Large B-Cell, Diffuse - classification ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - genetics ; Lymphoma, Large B-Cell, Diffuse - mortality ; molecular pathogenesis ; Neoplasm Proteins - genetics ; Neoplasm Proteins - metabolism ; Prednisone - administration & dosage ; Prednisone - therapeutic use ; Prognosis ; Survival Analysis ; Vincristine - administration & dosage ; Vincristine - therapeutic use]]></subject><ispartof>Best practice & research. Clinical haematology, 2012-03, Vol.25 (1), p.3-12</ispartof><rights>Elsevier Ltd</rights><rights>2012 Elsevier Ltd</rights><rights>Copyright © 2012 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-7967a7a414d5ab0ed211e54f91063a8719672df710bfa08b58a35395729aafdf3</citedby><cites>FETCH-LOGICAL-c410t-7967a7a414d5ab0ed211e54f91063a8719672df710bfa08b58a35395729aafdf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.beha.2012.01.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22409819$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Frick, Mareike, MD</creatorcontrib><creatorcontrib>Dörken, Bernd, MD</creatorcontrib><creatorcontrib>Lenz, Georg, MD</creatorcontrib><title>New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma</title><title>Best practice & research. Clinical haematology</title><addtitle>Best Pract Res Clin Haematol</addtitle><description>Diffuse large B-cell lymphoma and Burkitt lymphoma are two distinct lymphoma entities recognized by the current World Health Organization classification of lymphoid neoplasms. Although diagnostic criteria to distinguish these two subtypes have been established, a subset of cases have overlapping characteristics and therefore, the distinction can be challenging. Thus, the World Health Organization classification introduced an intermediate subtype referred as “B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma”. This review summarizes our current understanding of the biology of these lymphoma subtypes.</description><subject>Antibodies, Monoclonal, Murine-Derived - administration & dosage</subject><subject>Antibodies, Monoclonal, Murine-Derived - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Burkitt lymphoma</subject><subject>Burkitt Lymphoma - classification</subject><subject>Burkitt Lymphoma - drug therapy</subject><subject>Burkitt Lymphoma - genetics</subject><subject>Burkitt Lymphoma - mortality</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>diffuse large B-cell lymphoma</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - therapeutic use</subject><subject>Gene Expression Profiling</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Lymphoma, Large B-Cell, Diffuse - classification</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - genetics</subject><subject>Lymphoma, Large B-Cell, Diffuse - mortality</subject><subject>molecular pathogenesis</subject><subject>Neoplasm Proteins - genetics</subject><subject>Neoplasm Proteins - metabolism</subject><subject>Prednisone - administration & dosage</subject><subject>Prednisone - therapeutic use</subject><subject>Prognosis</subject><subject>Survival Analysis</subject><subject>Vincristine - administration & dosage</subject><subject>Vincristine - therapeutic use</subject><issn>1521-6926</issn><issn>1532-1924</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2PFCEQhonRuOvoH_BguHnqlqI_SYyJu_Er2ehBPROaLmaYpZsR6DX976Uz6x48yIXKy1tviqcIeQmsBAbtm2M54EGVnAEvGZSMVY_IJTQVL0Dw-vFWcyhawdsL8izGYzZUgldPyQXnNRM9iEtiv-Jvaudo94cUc5E8TQekg_XO71fqDZ28Q704FWhchrSeMG7qaI1ZItKs75FeFRqdo26dTgc_KarmkV4t4dam9CA-J0-MchFf3N878vPjhx_Xn4ubb5--XL-_KXQNLBWdaDvVqRrqsVEDw5EDYFMbAaytVN9Bfuej6YANRrF-aHpVNZVoOi6UMqOpduT1OfcU_K8FY5KTjdt4aka_RCl4J_q-hS47-dmpg48xoJGnYCcVVglMboTlUW6E5UZYMpAbwB15dR-_DBOODy1_kWbD27MB8yfvLAYZtcVZ42gD6iRHb_-f_-6fdu3sbLVyt7hiPPolzBmfBBlzj_y-7XhbMXCWT91VfwCiGaGw</recordid><startdate>20120301</startdate><enddate>20120301</enddate><creator>Frick, Mareike, MD</creator><creator>Dörken, Bernd, MD</creator><creator>Lenz, Georg, MD</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120301</creationdate><title>New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma</title><author>Frick, Mareike, MD ; Dörken, Bernd, MD ; Lenz, Georg, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-7967a7a414d5ab0ed211e54f91063a8719672df710bfa08b58a35395729aafdf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antibodies, Monoclonal, Murine-Derived - administration & dosage</topic><topic>Antibodies, Monoclonal, Murine-Derived - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Burkitt lymphoma</topic><topic>Burkitt Lymphoma - classification</topic><topic>Burkitt Lymphoma - drug therapy</topic><topic>Burkitt Lymphoma - genetics</topic><topic>Burkitt Lymphoma - mortality</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>diffuse large B-cell lymphoma</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - therapeutic use</topic><topic>Gene Expression Profiling</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Lymphoma, Large B-Cell, Diffuse - classification</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - genetics</topic><topic>Lymphoma, Large B-Cell, Diffuse - mortality</topic><topic>molecular pathogenesis</topic><topic>Neoplasm Proteins - genetics</topic><topic>Neoplasm Proteins - metabolism</topic><topic>Prednisone - administration & dosage</topic><topic>Prednisone - therapeutic use</topic><topic>Prognosis</topic><topic>Survival Analysis</topic><topic>Vincristine - administration & dosage</topic><topic>Vincristine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Frick, Mareike, MD</creatorcontrib><creatorcontrib>Dörken, Bernd, MD</creatorcontrib><creatorcontrib>Lenz, Georg, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Best practice & research. Clinical haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frick, Mareike, MD</au><au>Dörken, Bernd, MD</au><au>Lenz, Georg, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma</atitle><jtitle>Best practice & research. Clinical haematology</jtitle><addtitle>Best Pract Res Clin Haematol</addtitle><date>2012-03-01</date><risdate>2012</risdate><volume>25</volume><issue>1</issue><spage>3</spage><epage>12</epage><pages>3-12</pages><issn>1521-6926</issn><eissn>1532-1924</eissn><abstract>Diffuse large B-cell lymphoma and Burkitt lymphoma are two distinct lymphoma entities recognized by the current World Health Organization classification of lymphoid neoplasms. Although diagnostic criteria to distinguish these two subtypes have been established, a subset of cases have overlapping characteristics and therefore, the distinction can be challenging. Thus, the World Health Organization classification introduced an intermediate subtype referred as “B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma”. This review summarizes our current understanding of the biology of these lymphoma subtypes.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>22409819</pmid><doi>10.1016/j.beha.2012.01.003</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1521-6926 |
| ispartof | Best practice & research. Clinical haematology, 2012-03, Vol.25 (1), p.3-12 |
| issn | 1521-6926 1532-1924 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_927988617 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibodies, Monoclonal, Murine-Derived - administration & dosage Antibodies, Monoclonal, Murine-Derived - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Burkitt lymphoma Burkitt Lymphoma - classification Burkitt Lymphoma - drug therapy Burkitt Lymphoma - genetics Burkitt Lymphoma - mortality Cyclophosphamide - administration & dosage Cyclophosphamide - therapeutic use diffuse large B-cell lymphoma Doxorubicin - administration & dosage Doxorubicin - therapeutic use Gene Expression Profiling Gene Expression Regulation, Neoplastic Hematology, Oncology and Palliative Medicine Humans Lymphoma, Large B-Cell, Diffuse - classification Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - genetics Lymphoma, Large B-Cell, Diffuse - mortality molecular pathogenesis Neoplasm Proteins - genetics Neoplasm Proteins - metabolism Prednisone - administration & dosage Prednisone - therapeutic use Prognosis Survival Analysis Vincristine - administration & dosage Vincristine - therapeutic use |
| title | New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T11%3A40%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20insights%20into%20the%20biology%20of%20molecular%20subtypes%20of%20diffuse%20large%20B-cell%20lymphoma%20and%20Burkitt%20lymphoma&rft.jtitle=Best%20practice%20&%20research.%20Clinical%20haematology&rft.au=Frick,%20Mareike,%20MD&rft.date=2012-03-01&rft.volume=25&rft.issue=1&rft.spage=3&rft.epage=12&rft.pages=3-12&rft.issn=1521-6926&rft.eissn=1532-1924&rft_id=info:doi/10.1016/j.beha.2012.01.003&rft_dat=%3Cproquest_cross%3E927988617%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=927988617&rft_id=info:pmid/22409819&rft_els_id=S1521692612000047&rfr_iscdi=true |